Aim. As a part of ARGUS-2 program, to demonstrate the reserves for arterial hypertension (AH) control improvement, by rational monotherapy or combined therapy with diuretics in patients with uncontrolled AH in anamnesis: individuals with isolated systolic AH (ISAH), diabetes mellitus (DM), chronic nephropathy (CN), and metabolic syndrome (MS). Material and methods. This open, non-comparative study, without washout period, included 1438 patients (mean age 57,3±10,7 years, blood pressure, BP

more »

... ±14,2/93,4±10,0 mm Hg), not achieving target BP levels (<140/<90 mm Hg or <130/<80 mm Hg for DM or CN), and receiving non-diuretic therapy. Slow-release indapamide (Arifon® retard), in the dose of 1,5 mg, was administered once per day. Follow-up period lasted for 3 months. To achieve target BP levels, the physician could modify antihypertensive treatment regimen. Results. In total, 1399 patients (97,3%) completed the study. Arifon® retard was administered as monotherapy in 13,7% of the participants; as an alternative to previous ineffective monotherapy – in 6,8%; in addition to inadequately effective monotherapy – in 31,9%; and in addition to inadequately effective non-diuretic therapy – in 47,6%. Three months later, target BP level rate was 84,5%, mean BP level reduced to 131,8±9,7/80,5±6,9 mm Hg. Target BP was achieved in 91,9% (n=477) of ISAH patients, in 74,8% (n=214) of DM participants, in 75,6% (n=82) of CN individuals, and in 85,1% (n=745) of MS patients. Conclusion. The study results confirmed the importance of low-dose thiazide diuretic therapy, as a part of combined treatment, in achieving target BP levels among patients with high or very high cardiovascular risk.